To improve the quality of life of patients around the world through the development and delivery of high quality, innovative and easy to use therapeutic solutions.
in each other
in everything we do
for actions and results
to learn and grow
to new ideas and change
for self and others
of our business and goals
You may have heard of Repro Med Systems, Inc. That’s us! Today, we are operating as RMS Medical Products, a leading developer and manufacturer of medical devices and supplies. The company was incorporated in March, 1980 and is now publicly traded . Our stock symbol is REPR.
Worldwide, RMS Medical Products drives healthcare inspiration – in the minds of our patients, our employees, our customers and our shareholders – to give everyone greater freedom for living. We design and manufacture safe, affordable medical devices to make quality healthcare a reality for everyone.
We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers, and careful consideration for the patient experience. Our primary products are the FREEDOM60® and FreedomEdge® DynEQ Infusion Systems, RMS Precision Flow Rate Tubing™, HIgH-Flo Subcutaneous Safety Needle Sets™ and RES-Q-VAC® Hand Held Medical Suction.
We are passionate about helping people with our reliable medical devices made at our HQ in Chester, NY (USA). Our products, as well as product support, are offered worldwide by RMS and through a global network of distributors and service providers.
RMS is excited to expand into new markets with innovative, more technical products. We look forward to productive partnerships with people and companies who share our vision and can help us effectively deliver our value promise to stakeholders in our industry.
Conference Call Highlights: Refreshed, strengthened management team Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets Net Revenue increased 12.4% to $17.4 million from $15.4 million Adjusted EBITDA* expanded to $2.7 million, up 73.9% from $1.6 million in 2017 This presentation contains forward-looking statements that involve risks … Continued